Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Depreciation & Amortization (CF): 2023-2025

Historic Depreciation & Amortization (CF) for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $589,000.

  • Immunome's Depreciation & Amortization (CF) rose 43.31% to $589,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 76.96%. This contributed to the annual value of $1.6 million for FY2024, which is 220.00% up from last year.
  • Per Immunome's latest filing, its Depreciation & Amortization (CF) stood at $589,000 for Q3 2025, which was down 7.54% from $637,000 recorded in Q2 2025.
  • Immunome's 5-year Depreciation & Amortization (CF) high stood at $637,000 for Q2 2025, and its period low was $94,000 during Q1 2023.
  • In the last 3 years, Immunome's Depreciation & Amortization (CF) had a median value of $411,000 in 2024 and averaged $357,909.
  • Data for Immunome's Depreciation & Amortization (CF) shows a peak YoY spiked of 443.56% (in 2024) over the last 5 years.
  • Immunome's Depreciation & Amortization (CF) (Quarterly) stood at $194,000 in 2023, then skyrocketed by 148.97% to $483,000 in 2024, then surged by 43.31% to $589,000 in 2025.
  • Its Depreciation & Amortization (CF) was $589,000 in Q3 2025, compared to $637,000 in Q2 2025 and $611,000 in Q1 2025.